The tumor-targeting immunocytokine F16-IL2 in combination with doxorubicin: Dose escalation in patients with advanced solid tumors and expansion into patients with metastatic breast cancer

Cell Adhesion and Migration

Volumn 9, Issue 1-2, 2015, Pages 14-21

  Catania, Chiara ^a   Maur, Michela ^b   Berardi, Rossana ^c   Rocca, Andrea ^d   Di Giacomo, Anna Maria ^e   Spitaleri, Gianluca ^a   Masini, Cristina ^b   Pierantoni, Chiara ^c   González Iglesias, Reinerio ^f   Zigon, Giulia ^f   Tasciotti, Annaelisa ^f   Giovannoni, Leonardo ^f   Lovato, Valeria ^g   Elia, Giuliano ^g   Menssen, Hans D ^f   Neri, Dario ^h   Cascinu, Stefano ^c   Conte, Pier Franco ^b   De Braud, Filippo ⁱ  

^a EUROPEAN INSTITUTE OF ONCOLOGY   (Italy)

^b UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

^c UNIVERSITÀ POLITECNICA DELLE MARCHE   (Italy)

^d DEPARTMENT OF MEDICAL ONCOLOGY   (Italy)

^e UNIVERSITY HOSPITAL OF SIENA   (Italy)

^f Philogen SpA   (Italy)

^g PHILOCHEM AG   (Switzerland)

^h ETH ZURICH   (Switzerland)

ⁱ NATIONAL CANCER INSTITUTE   (Italy)

Author keywords

Antibody; Breast neoplasms; Clinical trial phase I; Immunocytokines; Interleukin 2

Indexed keywords

DOXORUBICIN; TELEUKIN; TENASCIN; ANTINEOPLASTIC AGENT; HYBRID PROTEIN; IL2 PROTEIN, HUMAN; INTERLEUKIN 2; MONOCLONAL ANTIBODY;

ADULT; AGED; ARTICLE; ASTHENIA; BREAST METASTASIS; CANCER CHEMOTHERAPY; CLINICAL ARTICLE; COMPUTER ASSISTED TOMOGRAPHY; CONSTIPATION; CONTROLLED STUDY; DISEASE CONTROL; DRUG DOSE ESCALATION; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; ENZYME LINKED IMMUNOSORBENT ASSAY; FEMALE; FEVER; HUMAN; IMMUNE RESPONSE; MALE; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; RECTUM HEMORRHAGE; SURFACE PLASMON RESONANCE; TREATMENT RESPONSE; TUMOR GROWTH; BREAST NEOPLASMS; CLINICAL TRIAL; METABOLISM; MIDDLE AGED; PATHOLOGY; TREATMENT OUTCOME;

ADULT; AGED; ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BREAST NEOPLASMS; DOXORUBICIN; FEMALE; HUMANS; INTERLEUKIN-2; MIDDLE AGED; RECOMBINANT FUSION PROTEINS; TREATMENT OUTCOME;

EID: 84939471750     PISSN: 19336918     EISSN: 19336926     Source Type: Journal    
DOI: 10.4161/19336918.2014.983785     Document Type: Article

References (21)

1. Kovacs JA, Vogel S, Albert JM, Falloon J, Davey RT Jr, Walker RE, Polis MA, Spooner K, Metcalf JA, Baseler M, et al. Controlled trial of interleukin-2 infusions in atients infected with the human immunodeficiency virus. N Engl J Med 1996; 335:1350-6; http://dx.doi.org/10.1056/NEJM199610313351803
2. Schmidinger M, Hejna M, Zielinski CC. Aldesleukin in advanced renal cell carcinoma. Expert Rev Anticancer Ther 2004; 4:957-80; http://dx.doi.org/10.1586/14737140.4.6.957
3. Atkins MB, Lotze MT, Dutcher JP, Fisher RI, Weiss G, Margolin K, Abrams J, Sznol M, Parkinson D, Hawkins M, et al. High-dose recombinant interleukin 2 therapy for patients with metastatic melanoma: analysis of 270 patients treated between 1985 and 1993. J Clin Oncol 1999; 17:2105-16
4. Helguera G, Morrison SL, Penichet ML. Antibodycytokine fusion proteins: harnessing the combined ower of cytokines and antibodies for cancer therapy. Clin Immunol 2002; 105:233-46; http://dx.doi.org/10.1006/clim.2002.5302
5. Schliemann C, Neri D. Antibody-based targeting of the tumor vasculature. Biochim Biophys Acta 2007; 1776:175-92
6. Schrama D, Reisfeld RA, Becker JC. Antibody targeted drugs as cancer therapeutics. Nat Rev Drug Discov 2006; 5:147-59; http://dx.doi.org/10.1038/nrd1957
7. Borsi L, Carnemolla B, Nicolo G, Spina B, Tanara G, Zardi L. Expression of different tenascin isoforms in normal, hyperplastic and neoplastic human breast tissues. Int J Cancer J Int du Cancer 1992; 52:688-92; http://dx.doi.org/10.1002/ijc.2910520504
8. Murphy-Ullrich JE, Lightner VA, Aukhil I, Yan YZ, Erickson HP, Hook M. Focal adhesion integrity is downregulated by the alternatively spliced domain of human tenascin. J Cell Biol 1991; 115:1127-36; http://dx.doi.org/10.1083/jcb.115.4.1127
9. Hindermann W, Berndt A, Borsi L, Luo X, Hyckel P, Katenkamp D, Kosmehl H. Synthesis and protein distribution of the unspliced large tenascin-C isoform in oral squamous cell carcinoma. J Pathol 1999; 189:475-80; http://dx.doi.org/10.1002/(SICI)1096-9896(199912)189:4%3c475::AIDPATH462%3e3.0.CO;2-V
10. Kusagawa H, Onoda K, Namikawa S, Yada I, Okada A, Yoshida T, Sakakura T. Expression and degeneration of tenascin-C in human lung cancers. Brit J Cancer 1998; 77:98-102; http://dx.doi.org/10.1038/bjc.1998.15
11. Katenkamp K, Berndt A, Hindermann W, Wunderlich H, Haas KM, Borsi L, Zardi L, Kosmehl H. mRNA expression and protein distribution of the unspliced tenascin-C isoform in prostatic adenocarcinoma. J athol 2004; 203:771-9; http://dx.doi.org/10.1002/path.1589
12. Hauptmann S, Zardi L, Siri A, Carnemolla B, Borsi L, Castellucci M, Klosterhalfen B, Hartung P, Weis J, Stocker G, et al. Extracellular matrix proteins in colorectal carcinomas. Expression of tenascin and fibronectin isoforms. Lab Invest; J Tech Methods Pathology 1995; 73:172-82
13. Carnemolla B, Castellani P, Ponassi M, Borsi L, Urbini S, Nicolo G, Dorcaratto A, Viale G, Winter G, Neri D, et al. Identification of a glioblastoma-associated tenascin-C isoform by a high affinity recombinant antibody. Am J Pathol 1999; 154:1345-52; http://dx.doi.org/10.1016/S0002-9440(10)65388-6
14. Castellani P, Dorcaratto A, Siri A, Zardi L, Viale GL. Tenascin distribution in human brain tumours. Acta neurochirurgica 1995; 136:44-50; http://dx.doi.org/10.1007/BF01411434
15. Marlind J, Kaspar M, Trachsel E, Sommavilla R, Hindle S, Bacci C, Giovannoni L, Neri D. Antibody-mediated delivery of interleukin-2 to the stroma of breast cancer strongly enhances the otency of chemotherapy. Clin Cancer Res 2008; 14:6515-24; http://dx.doi.org/10.1158/1078-0432.CCR-07-5041
16. Tacar O, Sriamornsak P, Dass CR. Doxorubicin: an update on anticancer molecular action, toxicity and novel drug delivery systems. J Pharm Pharmacol 2013; 65:157-70; http://dx.doi.org/10.1111/j.2042-7158.2012.01567.x
17. Brack SS, Silacci M, Birchler M, Neri D. Tumor-targeting roperties of novel antibodies specific to the large isoform of tenascin-C. Clin Cancer Res 2006; 12:3200-8; http://dx.doi.org/10.1158/1078-0432.CCR-05-2804
18. Therasse P, Arbuck SG, Eisenhauer EA, Wanders J, Kaplan RS, Rubinstein L, Verweij J, Van Glabbeke M, van Oosterom AT, Christian MC, et al. New guidelines to evaluate the response to treatment in solid tumors. European organization for research and treatment of cancer, national cancer institute of the United States, national cancer institute of Canada. J Natl Cancer Inst 2000; 92:205-16; http://dx.doi.org/10.1093/jnci/92.3.205
19. Eigentler TK, Weide B, de Braud F, Spitaleri G, Romanini A, Pflugfelder A, Gonzalez-Iglesias R, Tasciotti A, Giovannoni L, Schwager K, et al. A dose-escalation and signal-generating study of the immunocytokine L19-IL2 in combination with Dacarbazine for the therapy of patients with metastatic melanoma. Clin Cancer Res 2011; 17:7732-42; http://dx.doi.org/10.1158/1078-0432.CCR-11-1203
20. Johannsen M, Spitaleri G, Curigliano G, Roigas J, Weikert S, Kempkensteffen C, Roemer A, Kloeters C, Rogalla P, Pecher G, et al. The tumour-targeting human L19-IL2 immunocytokine: preclinical safety studies, phase I clinical trial in patients with solid tumours and expansion into patients with advanced renal cell carcinoma. Eur J Cancer 2010; 46:2926-35; http://dx.doi.org/10.1016/j.ejca.2010.07.033
21. Trotti A, Colevas AD, Setser A, Rusch V, Jaques D, Budach V, Langer C, Murphy B, Cumberlin R, Coleman CN, Rubin P. CTCAE v3.0: development of a comprehensive grading system for the adverse effects of cancer treatment. Seminars Rad Oncol, 2003; 13:176-81; http://dx.doi.org/10.1016/S1053-4296(03)00031-6